Best of Hematology and Breast Cancer 2025, Seattle

  03 Jan 2025 - 04 Jan 2025

   Seattle, WA, United States

conference-img

Best of Hematology and Breast Cancer 2025, Seattle

03 Jan 2025

 - 

04 Jan 2025

Seattle, WA, United States



The Best of Hematology and Breast Cancer 2025 conference in Seattle is a CME-accredited, in-person event providing healthcare professionals with the latest updates in managing hematology and breast cancer. Drawing insights from the 66th ASH Annual Meeting (ASH24) and the San Antonio Breast Cancer Symposium (SABCS24), the conference features expert presentations on recent research and its clinical implications.

Summarize the latest updates from ASH24 and SABCS24, focusing on their implications for clinical practice in managing hematologic disorders and breast cancer, Assess new therapeutic options for benign and malignant hematologic disorders and breast cancer, including appropriate indications and contraindications presented at ASH24 and SABCS24,

International Conference on Medical and Health Sciences

On: 25 May 2026

-

26 May 2026


International Conference on Sexual and Reproductive Health

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Medical and Health Sciences

On: 25 May 2026

-

26 May 2026


International Conference on Sexual and Reproductive Health

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026


International Conference on Cardiology and Cardiovascular Medicine

On: 25 May 2026

-

25 May 2026



Whats more on Hidoc Dr.


Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.

Recommended News For You

Conferences That Might Interest You

Recommended Articles For You

Boost Your Knowledge With These Quizzes





© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot